Court Ruled Liquidia Infringed Patent Claims
A district court ruling found Liquidia infringed two patent claims owned by United Therapeutics, potentially impacting YUTREPIA.
Updated on Sept. 30, 2026 in Biotech
Live Poll
Do you trust that patent litigation between drug companies generally puts patient needs first?
A federal district court ruled that Liquidia infringed on two claims within a United Therapeutics patent while finding other asserted claims invalid. Liquidia intends to appeal the decision and seek a label modification for its FDA-approved drug, YUTREPIA.
Why it matters
This patent dispute impacts the market trajectory of YUTREPIA, a drug approved for use in 2025. The ruling forces a pivot in commercial strategy as the companies move toward a final judgment on potential market restrictions.
The District of Delaware court identified 2 valid and infringed claims within the '327 patent, out of 6 total claims asserted by United Therapeutics. The status of the remaining 4 claims was dismissed as invalid.
The players
Liquidia
A pharmaceutical company based in Morrisville, N.C., focused on developing pulmonary hypertension therapies using its PRINT technology platform.
United Therapeutics
A biotechnology firm that develops therapies for pulmonary arterial hypertension and maintains a broad patent portfolio in respiratory medicine.
The details
The dispute centers on the '327 patent and the commercialization of YUTREPIA, an inhaled therapy approved by the FDA in 2025. Liquidia, headquartered in Morrisville, N.C., now plans to submit a supplement to its New Drug Application to excise the PH-ILD (pulmonary hypertension associated with interstitial lung disease) indication from the product label. This move serves as a potential mitigation strategy as the firm evaluates its legal appeal options.
Timeline
2025: YUTREPIA received FDA approval.
September 30, 2026: The District Court issued the ruling on patent claims.
October 7, 2026: The court-imposed deadline for parties to submit a form of judgment.
The Tech Race
This litigation follows the procedural patterns established by the Hatch-Waxman Act for resolving patent disputes between drug manufacturers. The outcome marks a critical inflection point in the competitive landscape for pulmonary hypertension treatments.
The court's decision may lead to changes in the label or availability of YUTREPIA for patients and healthcare providers. While Liquidia plans to appeal the ruling, the outcome of the impending judgment submission will dictate whether the drug remains accessible in its current form.
The takeaway
This case highlights the volatility of patent exclusivity in the pharmaceutical industry when navigating new therapeutic indications. Readers should monitor the October 7, 2026, judgment submission for details on the specific court-ordered restrictions affecting product labels.
What happens next
The parties are required to submit a form of judgment to the District of Delaware by October 7, 2026, which will clarify the scope of remedies and potential market restrictions.
Further reading
Learn more about the latest regulatory and legal shifts in the Biotech sector.
Live Poll
Do you trust that patent litigation between drug companies generally puts patient needs first?
